CNX Therapeutics wins two awards in two nights at CPHI Frankfurt

London, England and Frankfurt, Germany – 30 October 2025 – CNX Therapeutics, a specialty pharmaceutical company, has been recognised with two prestigious industry awards during CPHI week in Frankfurt, marking three awards in two months for the London-based pharmaceutical company.

In what has been an eventful and highly positive week at CPHI, the company won the 'At the Heart of Pharma' category at the CPHI Celebration evening, followed by 'CSR Programme of the Year' at the Global Generics and Biosimilars Awards the following night. Both awards recognise CNX's partnership with the Social Mobility Foundation (SMF), which brought five interns from underrepresented backgrounds into key business areas of the company.

The programme provided 12-month placements across CNX's Quality, Legal, Commercial, Data and People & Sustainability teams, using a values-based recruitment approach that focuses on potential rather than privilege.

"When you win three awards in two months, all recognising the same programme, you know you're onto something significant”, said Guy Clark, CEO of CNX Therapeutics. “Our partnership with the Social Mobility Foundation has given us access to exceptional talent – people who might never have had the chance to explore pharma careers otherwise. The fact we keep being recognised for this work underlines that our commitment to social mobility isn't a box-ticking exercise – it's core to who CNX is."

The double win at CPHI follows CNX's CSR Programme of the Year award at the Pharma Industry Awards in September, making it three major industry awards in two months. The company was also named finalist in the Pharma Company of the Year category at those awards.

‘We’re proud to create opportunities alongside CNX Therapeutics”, said Eloise Baker, Relationship Manager at SMF. “This award highlights our partnership’s impact and our shared commitment to ensuring young people from all backgrounds can thrive”.

The awards capped what has been a successful CPHI week for CNX, with strong engagement at the company's exhibition stand and positive conversations with partners and stakeholders across the pharmaceutical industry.

CNX Therapeutics was acquired by Inflexion Private Equity in 2021 and was recently selected by the mid-market private equity firm as one of four high-performing portfolio companies for Inflexion's Continuation Fund.